Effects of Lentivirus-Mediated C3 Expression on Trabecular Meshwork Cells and Intraocular Pressure

Junkai Tan,1 Ning Fan,1 Ningli Wang,2 BingKai Feng,1 Ming Yang,1 Guo Liu,1 Yun Wang,1 Xianjun Zhu,3 Paul L. Kaufman,4 Iok-Hou Pang,5 and Xuyang Liu1

1Shenzhen Key Laboratory of Ophthalmology, Shenzhen Eye Hospital, School of Optometry, Shenzhen University, Shenzhen, China
2Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China
3Institute of Laboratory Animal Sciences, Sichuan Academy of Medical Sciences and Sichuan Provincial Hospital, Chengdu, Sichuan, China
4Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, Wisconsin, United States
5Department of Pharmaceutical Sciences and North Texas Eye Research Institute, University of North Texas Health Sciences Center, Fort Worth, Texas, United States

Correspondence: Xuyang Liu, xliu1213@126.com.
JT and NF contributed equally to the work presented here and should therefore be regarded as equivalent authors.
Submitted: June 5, 2018
Accepted: September 4, 2018
Citation: Tan J, Fan N, Wang N, et al. Effects of lentivirus-mediated C3 expression on trabecular meshwork cells and intraocular pressure. Invest Ophthal Vis Sci. 2018;59:4937–4944. https://doi.org/10.1167/iovs.18-24978

PURPOSE. We evaluated the effects of lentivirus-mediated exoenzyme C3 transferase (C3) expression on cultured human primary trabecular meshwork (HTM) cells in vitro, and on rat intraocular pressure (IOP).

METHODS. HTM cells were cultured and treated with lentivirus vectors expressing either green fluorescent protein (GFP) only (LV-GFP) or GFP and C3 together (LV-C3-GFP). Changes in cell morphology and actin stress fibers were assessed. The vectors were also injected into the anterior chamber of rats, and GFP expression was visualized by a Micron III Retinal Imaging Microscope in vivo and a fluorescence microscope ex vivo. Changes in rat IOP were monitored by using a rebound tonometer and the eyes were evaluated by slit lamp.

RESULTS. LV-mediated C3 expression induced morphologic changes in HTM cells. The cells became retracted and rounded. GFP expression in the anterior chamber angle of rats was observed in vivo from 8 days to 48 days after injection of LV-C3-GFP or LV-GFP. IOP was significantly decreased in the LV-C3-GFP group starting 3 days post injection, and lasting for at least 40 days, when compared to either the contralateral control eyes (the LV-GFP group) or the ipsilateral baseline before injection (P < 0.05). No obvious inflammatory signs were observed in either the LV-C3-GFP or LV-GFP groups.

CONCLUSIONS. LV-mediated C3 expression induced changes in morphology of cultured HTM cells. Intracameral injection of LV-C3-GFP lowered rat IOP for at least 40 days. No significant inflammatory reactions were observed in either the LV-C3-GFP or LV-GFP groups. This study supports the possible use of C3 gene therapy for the treatment of glaucoma.

Keywords: lentivirus, C3 transferase, trabecular meshwork, rat, intraocular pressure

The actin cytoskeleton and its associated cellular interactions in the trabecular meshwork (TM) and juxtacanalicular tissue (JCT) contribute to aqueous outflow resistance. Direct or indirect actin-disruptive agents, such as the serine-threonine kinase inhibitor H-7 and latrunculins A and B, can disrupt the actin cytoskeleton and alter cell morphology and architecture in the TM and JCT, and thereby change the overall TM and Schlemm’s canal geometry and decrease outflow resistance. Rho-mediated signaling pathways regulate the assembly and contractility of the actomyosin network. Rho-associated protein kinase (ROCK) is one of the major downstream effectors of Rho GTPases, and the inhibition of ROCK lowers IOP of rats, rabbits, monkeys, and human patients with primary open-angle glaucoma.1–4 Exoenzyme C3 transferase (C3) is isolated from Clostridium botulinum and specifically inactivates Rho by ADP-ribosylation.5 We hypothesized that C3 has effects on aqueous outflow and IOP similar to ROCK inhibitors. Our previous work6 has shown that adenovirus-mediated C3 expression can significantly induce morphologic changes in human trabecular meshwork (HTM) cells and increase outflow facility in organ-cultured monkey anterior segments. In the current study, we report that lentivirus-mediated C3 delivery altered the cytoskeleton and its associated adhesions of cultured HTM cells and lowered intraocular pressure (IOP) in living rat eyes. Our findings support the possible use of C3 gene therapy for the treatment of glaucoma.

Materials and Methods

Viral Vectors

Recombinant lentivirus vectors, expressing either green fluorescent protein (GFP) alone (LV-GFP, 5 × 108 transducing units [TU]/mL) or GFP and C3 together (LV-C3-GFP, 8 × 108 TU/mL), were prepared by the Beijing LKL Gene Company (Beijing, China). Lentivirus vector expressed C3 driven by a cytomegalovirus (CMV) promoter and GFP via a murine cytomegalovirus (mCMV) promoter (Fig. 1A). Briefly, the C3 gene (657 bp) with restriction site and pLVX-mCMV-ZsGreen plasmid were digested with EcoRI/BamHI (New England Biolabs, Ipswich,
MA, USA) and linked to each other. Then the ligation products were transformed into *Escherichia coli* JM109 (Beijing LKL gene CO., Beijing, China) for further replication. The packing cell line, 293T cells (Beijing LKL gene CO.), was cotransfected with the recombinant transfer vector plasmid and lentiviral packaging vector plasmid for generation of lentiviral vectors. The viral packing supernatant was collected and centrifuged to obtain lentivirus particles. A 0.45-μm PVDF membrane filter (Merck Millipore, Billerica, MA, USA) provided sterilization, and the viral titer was evaluated by transducing HEK 293 cells, using a limiting dilution assay.

**Cell Culture**

Primary HTM cells (ScienCell Research Laboratories, Inc., Carlsbad, CA, USA; see http://www.sciencellonline.com for details) were cultured in TM Cell Medium (TMCM; ScienCell Research Laboratories) consisting of basal medium, 2% fetal bovine serum, 1% TM cell growth supplement (TMCGS) and 1% penicillin/streptomycin solution, at 37 °C in an atmosphere of 5% CO₂. The medium was changed every other day until the cells were approximately 90% confluent. Subsequently, cells were passed sequentially in a 1:4 ratio and maintained in the same medium. Cells of passages 4 to 5 were used in the experiments.

In a 24-well plate, HTM cells (5 × 10³ cells) were transduced with LV-C3-GFP or LV-GFP at multiplicities of infection (MOIs) of 80, 160, 400, 640, 800, and 1130. MOI was determined by simply dividing the number of viral particles added (mL added × TU/mL) by the number of cells added per well. The optimal MOIs were evaluated through detecting the expression of GFP and changes in morphology by using an IX71-Olympus inverted microscope with Nomarski optics (IX71; Olympus, Tokyo, Japan).

**Actin Labeling**

In a 6-well plate, primary HTM cells were cultured to 100% confluence (4 × 10⁵ cells) on coverslips precoated with poly-L-lysine for 1 week, at which time they exhibited a stable monolayer endothelial-like morphology. They were then transduced with LV-C3-GFP (MOI = 20 and 40) or LV-GFP (MOI = 20). Two days post treatment, the cells were washed with 1× DPBS (Dulbecco’s phosphate-buffered saline), fixed with 4% paraformaldehyde (Sigma-Aldrich Corp., St. Louis, MO, USA) for 10 minutes, and then permeabilized with 0.5% Triton X-100 (Sigma-Aldrich Corp.) for 4 minutes at room temperature. The cells were blocked with 1% bovine serum albumin (Sigma-Aldrich Corp.) for 20 minutes. Rhodamine-phalloidin (Thermo Fisher Scientific, Waltham, MA, USA) was used for fluorescent labeling of actin. Nuclei were counterstained with Fluoroshield containing 4',6-diamidino-2-phenylindole (Sigma-Aldrich Corp.). Images were captured by using a ZEISS ObserverZ1 fluorescence microscope equipped with a CCD camera (Carl Zeiss, Dublin, CA, USA). The percentage of cells with actin disruption was calculated as previously described.

**Animals**

All animals were maintained and handled in accordance with the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research. This study was approved by the Institutional Animal Care and Use Committee of Sichuan Academy of Medical Sciences. Experiments were performed on male Sprague-Dawley rats weighing 175 to 200 g, purchased from Vital River Laboratory Animal Technology Company (Beijing, China). All rats were housed in a room that remained at 22°C, 55% humidity, and 12-hour cycle lighting.
Viral Delivery to the Anterior Segment

Rats were anesthetized with 10% chloral hydrate (0.4 mL/100 g body weight; Sigma-Aldrich Corp.) given intraperitoneally. Lentivirus suspension was delivered to the anterior chamber by using a Hamilton glass syringe with a 26-gauge needle (10 μL volume, cemented needle, point style 2, needle length of 51 mm, needle outer diameter of 0.474 mm; Hamilton Corp., Reno, NV, USA). The corneas were anesthetized with 1 drop of 0.5% proparacaine hydrochloride (Alcaine; Alcon Laboratories, Inc., Fort Worth, TX, USA). All intracameral injections were monitored by direct visualization through an ophthalmic surgical microscope (Leica AG, Heerbrugg, Switzerland). The needle was inserted bevel-up through the peripheral cornea, and the length of the corneal puncture tunnel was approximately 1.0 to 1.5 mm. To allow for the subsequent injection volume and prevent leaking caused by injection-induced immediate elevation of IOP, a small amount of aqueous humor was released by lightly pressing the needle against the lower lip of the opening at the injection site. The anterior chamber shallowed but did not flatten upon release of aqueous humor, and it reformed immediately upon injection. 4 × 10⁶ TU (in 5–8 μL volume) of either LV-C3-GFP or LV-GFP was intracameral injected into contralateral eyes of each animal. The needle was left in the self-sealing entry site for 1 minute and then withdrawn quickly to prevent or minimize leaking. There might have been occasional iridial-needle touch upon releasing aqueous humor, but there was no iridial or lenticular corneal contact. The upturn at the start of the bevel creates a “heel” that protects the iris from becoming impaled on the needle tip as the chamber shallows. The outer diameter of the needle is 474 μm, the central axial depth of the rat anterior chamber is ~1.0 mm. Ofloxacin Ophthalmic Ointment (Santen, Inc., Tokyo, Japan) was topically administered to prevent ocular infection.

Clinical Examination of the Rat Eye

To check the GFP expression, rat eyes were first set up under the bright field image of a Micron III Retinal Imaging Microscope (Phoenix Research Laboratories, Pleasanton, CA, USA) to assure that the eye was in the correct position. The anterior segments were thus also examined before looking for the pretreatment and each time point after injection in the LV-C3-GFP and LV-GFP groups. The variance was not homogeneous, so Tamhane’s T2 post hoc test was used. The fluorescent image system of a Micron III Retinal Imaging Microscope was used to evaluate GFP expression in rat eyes. Rats were anesthetized with an intraperitoneal injection of 10% chloral hydrate and placed on the microscope platform. The area of anterior segment was exposed gently by using a blunt tweezer. Image focusing was achieved by adjusting the platform. Rat position and angle relative to the microscope were altered for image acquisitions of the different quadrants of the anterior segment. After adjusting the brightness (maximum exciting light, 17 Gain and 4 frames per second for GFP detection), phase contrast and fluorescence images were captured, and analyzed by Image-Pro Plus software (Version 6.0; Media Cybernetics, Rockville, MD, USA). If the fluorescence continually remained visible in a quadrant, the fluorescent intensities at all time points were quantified by integrated optical density (IOD; Area × Average Density) and charted with Microsoft Office Excel 2016 software (Version 1805; Microsoft, Inc., Redmond, WA, USA).

Ex Vivo Fluorescence Microscopy

Rat ocular globes were enucleated immediately after euthanization and immersed in fresh 4% paraformaldehyde in PBS overnight. Each globe was then bisected at the equator; the lens was removed, and wedge-shaped specimens containing the anterior chamber angle region with the TM were fixed for an additional hour. Specimens were then washed in 50% sucrose (4°C, overnight), embedded in OCT (Sakura Finetek USA, Inc., Torrance, CA, USA), and then frozen in liquid nitrogen. Meridional 10-μm sections were mounted on a microscope slide (Citotest Labware Manufacturing Co., Ltd., Nanjing, China) and GFP was visualized with a Leica DM4 microscope (DM400B; Leica, Wetzlar, Germany).

Statistics

SPSS 18 software (IBM-SPSS, Chicago, IL, USA) was used for all statistics. Paired Student’s t-test was used for the IOP comparison between the LV-C3-GFP and LV-GFP groups at the same time point after intracameral injection, and between the pretreatment and each time point after injection in the LV-GFP or LV-C3-GFP groups. One-way ANOVA was used to compare the differences of actin disruption among the three groups (including medium-only–treated control, LV-C3-GFP and LV-GFP groups). The variance was not homogeneous, so Tamhane’s T2 post hoc test was used. P value of < 0.05 was regarded as statistically significant. Data are presented as mean ± SEM.

RESULTS

Effects of C3 on HTM Cell Morphology and Actin Stress Fibers

Under our study and observation conditions, control HTM cells showed a dark polygonal shape with ruffled borders and did not show green fluorescence (Fig. 1B). Compared to the controls, HTM cells transduced with LV-C3-GFP appeared to be either elongated or rounded up at 24 hours after exposure, and the morphologic changes lasted for more than 6 days (end of observation, Fig. 1B). The number of cells showing altered morphology increased with higher MOI values, and the cells displayed cytotoxicity at MOI of 1130 (volume = 7 μL, data not shown).

Since the C3-induced morphologic changes in HTM cells were already obvious at MOI of 80, lower MOIs of 20 and 40...
were chosen for the actin-labeling experiment (volume = 10 µL and 20 µL). LV-GFP–treated and medium-only–treated cells served as viral-only and negative controls, respectively. HTM cells formed an endothelial-like monolayer with extensive intercellular contacts. As shown in Figure 2, widened intercellular spaces were found in the LV-C3-GFP-treated cells, but were not detected in the controls. There was a loss of stress fibers in cells treated with LV-C3-GFP at MOI of 20 and 40. Additionally, quantitatively significant differences in actin cytoskeleton disruption (cell rounding) were detected among the three groups, that is, LV-C3-GFP at MOI of 20, LV-GFP at MOI of 20 (volume = 16 µL), and the medium-only–treated control (Table 1). Group assignments and summary of transducing conditions are described in Table 2.

**GFP Expression in the Anterior Segment of Rats**

Expression of GFP after intracameral injection of LV-GFP or LV-C3-GFP was evaluated by two methods: in vivo examination and examination of postmortem ocular tissues. The rats’ eyes injected intracameral with 4 × 10⁶ TU LV-C3-GFP showed positive fluorescence (fluorescent spots and/or confluent fluorescence) in the anterior chamber angle, and in particular, the region of the TM (Fig. 3A). This fluorescence was detected first at 8 days (n = 14; 7 of 14 injected eyes) and intense at 16 days (n = 10; 8 of 10 injected eyes), 21 days (n = 8; 5 of 8 injected eyes), and 35 days (n = 7; 4 of 7 injected eyes), and again weakened at 48 days (n = 6; 3 of 6 injected eyes) (Table 3). There were three eyes in each of the LV-C3-GFP and LV-GFP groups that still showed green fluorescence in the nasal anterior chamber angle at euthanasia (Fig. 3C).

**TABLE 1.** Percentage of Cells With Actin Disruption

| Group          | MOI = 20 | MOI = 20 | P     |
|----------------|----------|----------|-------|
| Mock           |          |          |       |
| LV-GFP         | 127 ± 1  | 126 ± 11 | <0.001|
| LV-C3-GFP      | 136 ± 13 | 18 ± 0.004† |       |

Mean ± SEM of three ×40 fields (310 × 250 µm); percentage of DAPI-stained nuclei showing actin disruption in cytoplasm; n, number of cells showing actin disruption in cytoplasm; n, total number of DAPI-stained nuclei.

† Significance of differences among three groups: 1-way ANOVA.

§ Tamhane’s T2 test: P < 0.01 (LV-C3-GFP MOI = 20 versus either LV-GFP MOI = 20 or medium-only–treated control).

**Figure 2.** Actin organization in confluent 6-well plate monolayers of HTM cells 48 hours after transduction with lentivirus vectors. Actin was labeled with rhodamine-phalloidin (red fluorescence) and cell nuclei were labeled by DAPI (blue). Compared to LV-GFP–treated (MOI = 20) and medium-only–treated (mock) HTM cells, significant cell rounding and actin reorganization (enlarged inset images) were found in the cells receiving LV-C3-GFP (MOI = 20 or 40). Black scale bar = 100 µm. White scale bar = 50 µm. The percentage of cells in each condition exhibiting actin disruption is shown in Table 1.

**IOP Change in Rats Transduced With Lentiviral Vectors**

Results of the effect of LV-C3-GFP intracameral injection on live rat IOP are shown in Figure 4. The pretreatment IOP was 11.24 ± 0.14 mm Hg (mean ± SEM, n = 14) and 11.41 ± 0.15 mm Hg in LV-GFP–treated and LV-C3-GFP–treated eyes, respectively, and there was no statistical difference in the baseline values of IOP between the two groups (P > 0.05). The IOP in the LV-GFP–treated eyes did not show significant change, compared to the pretreatment IOP (P > 0.05) over the course of the experiment. LV-C3-GFP (4 × 10⁶ TU) significantly lowered IOP in rats from 3 to 42 days after injection, when compared to the
contralateral LV-GFP–injected eyes \( (P < 0.05) \), with an initial difference of \( 1.83 \pm 0.47 \) mm Hg on day 3 post injection \( (n = 14; P < 0.01) \) and a maximal difference of \( 3.63 \pm 0.83 \) mm Hg on day 28 \( (n = 7; P < 0.01) \). When compared to pretreatment IOP, there was a significant decrease in IOP in the LV-C3-GFP–treated eyes from 3 to 42 days \( (P < 0.05) \), with an initial difference of \( 1.97 \pm 0.40 \) mm Hg on day 3 post injection \( (n = 14; P < 0.001) \) and a maximal decrease of \( 2.80 \pm 0.25 \) mm Hg on day 21 \( (n = 7; P < 0.001) \). The IOP changes loosely approximated, but were not highly concordant with, the time-dependent expression changes of GFP (Fig. 4B). Further, minimal expression of the \( C3 \) gene, if reflected by GFP expression, produced near-maximal IOP reduction, while maximal gene expression had little further effect on IOP.

**Monitoring Inflammation in the Rat Anterior Segment After Injection**

No surgical complications, such as hyphema or cataract, occurred in the study. Rat eyes injected with LV-C3-GFP showed neither lens nor corneal opacity, or any signs of inflammation such as exudation, conjunctival or iridal hyperemia, corneal edema or anterior chamber cells or flare at any time points during the experiment, and were indistinguishable from the LV-GFP–injected eye (Fig. 5).

**DISCUSSION**

We have reported previously that adenovirus-mediated \( C3 \) expression significantly induces morphologic changes in HTM cells and increases outflow facility in organ-cultured monkey anterior segments.6 In this study, we confirmed that lentivirus-mediated \( C3 \) expression induced cell rounding and actin reorganization in HTM cells, and report, for the first time to the best of our knowledge, the IOP-lowering effect of lentiviral vector containing the \( C3 \) gene in live rats.

The Rho/ROCK pathway plays a crucial role in IOP modulation of both normal and glaucomatous eyes. Many studies have demonstrated that ROCK inhibitors, such as Y-27632, H-1152, and ripasudil (K-115), increase outflow facility and reduce IOP in rats, rabbits, monkeys, and human patients.1–4,11,12 In addition, RhoA-siRNA effectively reduces IOP in mice by inhibiting RhoA,13 but this inhibition is

---

### Table 2. Group Assignments and Summary of Transduction for Cell Culture Study

| Group       | Titer, TU/mL | Culture Plate | CN, Cells/Well | MV, mL/Well | MOI | VV, µL | TUs |
|-------------|--------------|---------------|----------------|-------------|-----|-------|-----|
| LV-C3-GFP   | \( 8.0 \times 10^8 \) | 24-well       | \( 5.0 \times 10^5 \) | 0.5         | 80  | 0.5   | \( 4.0 \times 10^5 \) |
|             |              | 6-well        | \( 4.0 \times 10^5 \) | 1.5         | 20  | 10.0  | \( 8.0 \times 10^6 \) |
| LV-GFP      | \( 5.0 \times 10^8 \) | 24-well       | \( 5.0 \times 10^5 \) | 0.5         | 80  | 0.8   | \( 4.0 \times 10^3 \) |
|             |              | 6-well        | \( 4.0 \times 10^5 \) | 1.5         | 20  | 16.0  | \( 8.0 \times 10^6 \) |

CN, cell numbers per well in culture plate; MV, medium volume per well; VV, virus volume.

---

![Figure 3](image-url)
generally accompanied by a massively increased RhoB expression, which partially compensates for the cellular functions of RhoA.14 C3, a 24-kDa single-chain protein from Clostridium botulinum,15 avoids this compensation by inhibiting all Rho isomers, including RhoA, RhoB, and RhoC. In our previous study, an adenoviral vector has been used to deliver C3 into the anterior chamber of organ-cultured monkey anterior segments and significantly increases outflow facility for at least 6 days. In a similar study, self-complementary adeno-associated virus serotype 2 carrying the mutated RhoA complementary DNA (scAAV2.dnRhoA) prevents elevation of nocturnal IOP in rats for at least 4 weeks.16 In the current study, lentivirus-mediated delivery of C3 also induced IOP lowering for more than 40 days in rat eyes. These studies indicate that IOP lowering can be achieved by inhibiting the Rho/ROCK pathway, and that expressing the C3 gene in the TM may be an effective approach for glaucoma therapy.

We chose lentivirus as a vector for C3 transduction among various viral vectors after comparing their characteristics. Adenovirus (AdV), adeno-associated virus (AAV), herpes simplex virus (HSV), type C-retrovirus, and lentivirus are the commonly used viral vectors for ocular gene therapy trials.17 AdV and HSV often show different degrees of immunogenicity and limited expression durations.18,19 The type C-retrovirus cannot be used to transduce nondividing cells20 and appears to be oncogenic.21 The AAV vectors usually show lower immunogenicity and persistent expression22,23 and have been used in inherited disease studies, especially retinal and optic nerve diseases.24,25 The transduction efficiency of conventional AAVs in TM seems very low because it is hard for AAVs to form the double-stranded DNA by themselves.26 The scAAVs overcome this problem by bypassing the required second-strand DNA synthesis, and could be transduced in TM efficiently.27–29 However, the size of scAAV expression cassette is very limited, and in addition, the vector appears to be capable of transducing corneal endothelium (data not shown). Lentiviruses have large packaging capacity and can be integrated genomically into nondividing and dividing cells.30 Lentiviral vectors have the capacity of long-term efficient transduction in TM, either ex vivo or in vivo.31,32 Our studies showed that the C3-expressing lentiviral vector-mediated IOP-lowering effect lasted for 42 days, and GFP expression for at least 55 days in rat eyes. Similar results33 are reported in cats and monkeys with the Feline immunodeficiency virus (FIV-)

**TABLE 3.** Summary of GFP Expression in the Anterior Chamber Angle of Rats After Injections

| Group                | Days | 8   | 16  | 21  | 35  | 48  |
|----------------------|------|-----|-----|-----|-----|-----|
| LV-C3-GFP (in vivo)  | n    | 14  | 10  | 8   | 7   | 6   |
| Positive             |      | 7   | 8   | 7   | 4   | 3   |
| Negative             |      | 7   | 2   | 1   | 3   | 3   |
| Ratio                |      | 0.50| 0.80| 0.88| 0.57| 0.50|
| LV-C3-GFP (ex vivo)  | n    | 2   | 2   | 1   | 1   | 6   |
| Positive             |      | 2   | 2   | 1   | 1   | 6   |
| Negative             |      | 0   | 0   | 0   | 0   | 0   |
| Ratio                |      | 1.00| 1.00| 1.00| 1.00| 1.00|
| LV-GFP (in vivo)     | n    | 14  | 10  | 8   | 7   | 6   |
| Positive             |      | 8   | 7   | 5   | 4   | 3   |
| Negative             |      | 6   | 3   | 3   | 3   | 3   |
| Ratio                |      | 0.57| 0.70| 0.63| 0.57| 0.50|
| LV-GFP (ex vivo)     | n    | 2   | 2   | 1   | 1   | 6   |
| Positive             |      | 2   | 2   | 1   | 1   | 6   |
| Negative             |      | 0   | 0   | 0   | 0   | 0   |
| Ratio                |      | 1.00| 1.00| 1.00| 1.00| 1.00|

* Two rats dropped out of the examination on day 8 (accidental death)

![Image](image-url)
mediated prostaglandin F synthase and GFP expression. There are several possible explanations for the gradual loss of transgene expression. Species-specific restriction factors from the host might block lentiviral infection, or the CMV promoter could be silenced in the host.\(^{35-36}\) In addition, our study showed that the GFP expression of the LV-GFP-injected eyes was stronger than that of the LV-C3-GFP-injected eyes after same amount of virus injections, but the reason remained unclear. It might be possible that expression of one gene was more efficient than simultaneously expressing two genes.

The current study showed that approximately two-thirds of the maximal IOP lowering effect was achieved with gene expression levels barely off the baseline, as shown in Figure 4B. Even though the two events were not coincident, there was a substantial IOP effect along with substantial gene expression. The reasons for the difference between fluorescence intensity and IOP lowering have not been identified, but may be explained partly by the inherent variabilities of the two parameters. However, it was also plausible that a small increase in GFP expression (as indicated by a small change in IOD) correlated with an expression level of C3 sufficient to produce the two-thirds maximal observed IOP reduction and that further increase in C3 expression produced more modest further changes in IOP. This is supported, at least in part, by the fact that the C3 expression was associated with GFP expression both in the cultured HTM cells and the live animals.

The undiluted lentiviral vectors containing the same transducing unit in different volumes (8 \(\muL\) for controls and 5 \(\muL\) for C3-treated group) were used to transduce rat eyes. Compared to the baseline, the IOP in LV-GFP-treated eyes did not change significantly during the experiment (from day 3 to day 42 post injection), indicating that the “overfill” in the control eyes did not affect the results. 26G needles were used for intracameral injections. No obvious injection-related complications such as iridal hyperemia or hyphema were found. There might have been occasional iridal-neckleuch touch upon release of aqueous humor, but the needle, with the tip bevel-up and upturned, remained stationary, with the heel not rubbing against the iris or the needle tip touching the corneal endothelium. The central anterior chamber depth (~1.0 mm) was approximately twice the needle outer diameter (~0.47 mm). There was no iris deformation, iridal or lenticular corneal contact. Nonetheless, we realize that smaller-diameter needles would provide a bigger safety margin and be easier to handle for such experiments.

We did not anesthetize the animals and examine the eyes with either the Micron III or the slit lamp shortly after the injection, believing that rest for the rats was more important. However, by looking at the experimental eyes closely with our naked eyes, no obvious abnormalities such as ocular surface exudation or anterior chamber hyphema were detected. The anterior segment was examined each time when the GFP expression was checked. No abnormalities were found either (data not shown). However, the possible presence of mild and transient inflammatory reactions caused by either the injection of the vector or its transgene expression could not be ruled out for the first week post injection.

In summary, this study demonstrated that lentiviral vector-mediated C3 expression effectively induced morphologic changes and disruption of the actin cytoskeleton in primary HTM cells, and reduced IOP in rats. Thus, a lentivirus-C3 construct might be used to achieve a relatively durable IOP-lowering effect as gene therapy for glaucoma. However, the C3 expression was lost after 42 days, and in live monkeys the prostaglandin F synthase effect was not lost until 5 months. Although GFP expression in the TM could be achieved for more than 2 years in live monkeys from either an FIV\(^{57}\) or scAAV\(^{57}\) platform, neither platform carrying a C3 transgene has yet produced an IOP effect (PLK, unpublished data). Obviously, further studies are needed.

Acknowledgments

Supported by the National Natural Science Foundation of China (NSFC Grant Nos. 81770924 and 81500718) and Sanming Project of Medicine in Shenzhen (No. SZSM201512045). National Institutes of Health/National Eye Institute Core Grant for Vision Research 2 P30 EY001665 to University of Wisconsin-Madison, and unrestricted departmental grants from Research to Prevent Blindness, New York, New York, and the Ocular Physiology Research & Education Foundation, Madison, Wisconsin, assisted PLK’s efforts.

Disclosure: J. Tan, None; N. Fan, None; N. Wang, None; B. Feng, None; M. Yang, None; G. Liu, None; Y. Wang, None; X. Zhu, None; P.L. Kaufman, None; L.-H. Pang, None; X. Liu, None

References

1. Inazaki H, Kobayashi S, Anzai Y, et al. One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy. Graefes Arch Clin Exp Ophthalmol. 2017; 255:2009–2015.
2. Kaneko Y, Ohta M, Isobe T, Nakamura Y, Mizuno K. Additive intraocular pressure-lowering effects of Ripasudil with glaucoma therapeutic agents in rabbits and monkeys. J Ophthalmol. 2017:2017:7079645.
3. Toris CB, McLaughlin MA, Dworak DP, et al. Effects of Rho kinase inhibitors on intraocular pressure and aqueous humor dynamics in nonhuman primates and rabbits. J Ocul Pharmacol Ther. 2016;32:355–364.
4. Yu M, Chen X, Wang N, et al. H-1152 effects on intraocular pressure and trabecular meshwork morphology of rat eyes. J Ocul Pharmacol Ther. 2008;24:373–379.
5. Aktories K, Mohr C, Koch G. Clostridium botulinum C3 ADP-ribose transferase. Curr Top Microbiol Immunol. 1992;175: 115–131.
6. Liu X, Hu Y, Filla MS, et al. The effect of C3 transgene expression on actin and cellular adhesions in cultured human trabecular meshwork cells and on outflow facility in organ cultured monkey eyes. Mol Vis. 2005;11:1112–1121.
7. Yu N, Zhang Z, Chen P, et al. Tetramethylpyrazine (TMP), an active ingredient of Chinese herb medicine chuanxiong, attenuates the degeneration of trabecular meshwork through SDF-1/CXCR4 axis. PLoS One. 2015;10:e0133055.
8. Inoue-Mochita M, Inoue T, Fujimoto T, et al. p38 MAP kinase inhibitor suppresses transforming growth factor-\(\beta\)-induced type 1 collagen production in trabecular meshwork cells. PLoS One. 2015;10:e0120774.
9. Slausson SR, Peters DM, Schwinn MK, Kaufman PL, Gabelt BT, Brandt CR. Viral vector effects on exoenzyme C3 transferase-mediated actin disruption and on outflow facility. Invest Ophthalmol Vis Sci. 2015;56:2431–2438.
10. Wang WH, Millar JC, Pang IH, Wax MB, Clark AF. Noninvasive measurement of rodent intraocular pressure with a rebound tonometer. Invest Ophthalmol Vis Sci. 2005;46:4617–4621.
11. Honjo M, Tanihara H, Inatani M, et al. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci. 2001;42:137–144.
12. Kaneko Y, Ohta M, Inoue T, et al. Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm’s canal endothelial cells. Sci Rep. 2016;6:19640.
13. Liu Q, Wu K, Qiu X, Yang Y, Lin X, Yu M. siRNA silencing of gene expression in trabecular meshwork: RhoA siRNA reduces IOP in mice. Curr Mol Med. 2012;12:1015–1027.
14. Ho TT, Merajver SD, Lapierre CM, Nusgens BV, Deroanne CF. RhoA-GDP regulates RhoB protein stability: potential involvement of RhoGDIalpha. *J Biol Chem*. 2008;283:21588–21598.

15. Aktories K, Wilde C, Vogelsang M. Rho-modifying C3-like ADP-ribosyltransferases. *Rev Physiol Biochem Pharmacol*. 2004;152:1–22.

16. Borrás T, Buie LK, Spiga MG, Carabana J. Prevention of nocturnal elevation of intraocular pressure by gene transfer of dominant-negative RhoA in rats. *JAMA Ophthalmol*. 2015;133:182–190.

17. Dang Y, Loewen R, Parikh HA, Roy P, Loewen NA. Gene transfer to the outflow tract. *Exp Eye Res*. 2017;158:73–84.

18. Liu X, Brandt CR, Gabelt BT, Bryar PJ, Smith ME, Kaufman PL. Herpes simplex virus mediated gene transfer to primate ocular tissues. *Exp Eye Res*. 1999;69:385–395.

19. Borrás T, Gabelt BT, Klintworth GK, Peterson JC, Kaufman PL. Non-invasive observation of repeated adenoviral GFP gene delivery to the anterior segment of the monkey eye in vivo. *J Gene Med*. 2001;3:437–449.

20. Lewis PF, Emerman M. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. *J Virol*. 1994;68:510–516.

21. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. *Science*. 2003;300:1749–1751.

22. Mannon CS, Pierce GE, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. *Nat Med*. 2006;12:342–347.

23. Murphy SL, High KA. Gene therapy for haemophilia. *Br J Haematol*. 2008;140:479–487.

24. Bennett J, Ashtari M, Wellman J, et al. AA2 gene therapy readministration in three adults with congenital blindness. *Sci Transl Med*. 2012;4:120ra15.

25. Jacobson SG, Cideciyan AV, Ratnakaram R, et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 5 years. *Arq Ophtalmol*. 2012;130:9–24.

26. Borrás T, Xue W, Choi VW, et al. Mechanisms of AAV transduction in glaucoma-associated human trabecular meshwork cells. *J Gene Med*. 2006;8:589–602.

27. Buie LK, Rasmussen CA, Porterfield EC, et al. Self-complementary AAV virus (scAAV) safe and long-term gene transfer in the trabecular meshwork of living rats and monkeys. *Invest Ophtalmol Vis Sci*. 2010;51:236–248.

28. McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. *Gene Ther*. 2001;8:1248–1254.

29. McCarty DM, Fu H, Monahan PE, Toulson CE, Naik P, Samulski RJ. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. *Gene Ther*. 2003;10:2112–2118.

30. Loewen N, Leske DA, Cameron JD, et al. Long-term retinal transgene expression with FIV versus adenoviral vectors. *Mol Vis*. 2004;10:272–280.

31. Loewen RT, Roy P, Park DB, et al. A porcine anterior segment perfusion and transduction model with direct visualization of the trabecular meshwork. *Invest Ophtalmol Vis Sci*. 2016;57:1338–1344.

32. Loewen N, Fautsch MP, Peretz M, et al. Genetic modification of human trabecular meshwork with lentiviral vectors. *Hum Gene Ther*. 2001;12:2109–2119.

33. Lee ES, Rasmussen CA, Filla MS, et al. Prospects for lentiviral vector mediated prostaglandin F synthase gene delivery in monkey eyes in vivo. *Curr Eye Res*. 2014;39:859–870.

34. Teschendorf C, Warrington KH, Siemann DW, Muzyczka N. Comparison of the EF-1 alpha and the CMV promoter for engineering stable tumor cell lines using recombinant adeno-associated virus. *Anticancer Res*. 2002;22:3325–3330.

35. Zeng X, Chen J, Sanchez JF, et al. Stable expression of hrGFP by mouse embryonic stem cells: promoter activity in the undifferentiated state and during dopaminergic neural differentiation. *Stem Cells*. 2003;21:647–653.

36. Challa P, Luna C, Liton PB, et al. Lentiviral mediated gene delivery to the anterior chamber of rodent eyes. *Mol Vis*. 2005;11:425–430.

37. Khare PD, Loewen N, Teo W, et al. Durable, safe, multi-gene lentiviral vector expression in feline trabecular meshwork. *Mol Tber*. 2008;16:97–106.